Current guidelines recommend triple antithrombotic therapy (TT) consisting of warfarin, aspirin, and a P2Y12 inhibitor following an anterior ST elevation myocardial infarction (STEMI) complicated by extensive wall motion abnormalities. This recommendation, however, is based on data collected before percutaneous coronary intervention (PCI) became the standard of care for the treatment of STEMI. We designed a retrospective study of patients who received PCI for anterior STEMI over an 8-year period to compare rates of thromboembolic and bleeding events between patients receiving dual antiplatelet therapy (DAPT) and those receiving TT, including warfarin. Patients were included if the predischarge echocardiogram showed extensive wall motion abnormality and an ejection fraction ≤35%. Patients with known left ventricular thrombus were excluded. A total of 124 patients met the criteria, with 80 patients in the DAPT group and 44 in the TT group. The median age was 58 years in the TT group and 64 years in the DAPT group (P < 0.04), with an average ejection fraction of 31%. Thromboembolic events occurred in 4 patients (5%) in the DAPT group compared with 3 patients (6.8%) in the TT group (P = 0.70). Bleeding occurred in 2 patients in the DAPT group and 4 patients in the TT group (2.5% in DAPT vs. 9.1% in TT group, P = 0.18). No differences in rates of clinical embolism or left ventricular thrombus were found. Our data support recent findings that warfarin may not be indicated for patients following PCI for anterior STEMI, even when significant wall motion abnormalities and reduced ejection fraction ≤35% are present.
Current guidelines recommend triple antithrombotic therapy (TT) consisting of warfarin, aspirin, and a P2Y12 inhibitor following an anterior ST elevation myocardial infarction (STEMI) complicated by extensive wall motion abnormalities. This recommendation, however, is based on data collected before percutaneous coronary intervention (PCI) became the standard of care for the treatment of STEMI. We designed a retrospective study of patients who received PCI for anterior STEMI over an 8-year period to compare rates of thromboembolic and bleeding events between patients receiving dual antiplatelet therapy (DAPT) and those receiving TT, including warfarin. Patients were included if the predischarge echocardiogram showed extensive wall motion abnormality and an ejection fraction ≤35%. Patients with known left ventricular thrombus were excluded. A total of 124 patients met the criteria, with 80 patients in the DAPT group and 44 in the TT group. The median age was 58 years in the TT group and 64 years in the DAPT group (P < 0.04), with an average ejection fraction of 31%. Thromboembolic events occurred in 4 patients (5%) in the DAPT group compared with 3 patients (6.8%) in the TT group (P = 0.70). Bleeding occurred in 2 patients in the DAPT group and 4 patients in the TT group (2.5% in DAPT vs. 9.1% in TT group, P = 0.18). No differences in rates of clinical embolism or left ventricular thrombus were found. Our data support recent findings that warfarin may not be indicated for patients following PCI for anterior STEMI, even when significant wall motion abnormalities and reduced ejection fraction ≤35% are present.
A cute thromboembolic events due to left ventricular thrombus (LVT) formation, particularly in patients with reduced ejection fraction (EF), remain a risk for patients surviving an anterior ST elevation myocardial infarction (STEMI) (1) . Th e reported incidence of LVT formation and subsequent embolization varies based on the timing of the echocardiographic examination and the diagnostic, anticoagulation, and reperfusion strategies utilized in managing the initial presentation but is noted to range from 0 to as high as 86% (1) (2) (3) (4) (5) (6) (7) (8) (9) . Warfarin as a prophylactic strategy is therefore utilized and suggested in guidelines based on data derived from pooled results of studies done before catheter-based treatment of STEMI was prominent (10, 11) . A recent report by Le May et al has suggested that warfarin treatment might be unnecessary in patients managed by primary PCI and dual antiplatelet therapy (DAPT) (12) . Th e potential adequacy of DAPT alone was also shown in a small study that showed no advantage to a triple therapy (TT) regimen involving aspirin, a P2Y12 inhibitor, and warfarin when compared with DAPT with aspirin and a P2Y12 inhibitor in preventing LVT and systemic embolism (13) . Given the uncertain benefi t and known bleeding risk associated with TT (14), we conducted a retrospective analysis spanning 8 years to compare the rates of LVT formation and thromboembolic events in patients with STEMI with EF ≤35% managed with DAPT alone versus TT.
METHODS
Th is was a retrospective, single-center study of patients presenting with anterior wall myocardial infarction (MI) between January 2003 and November 2012 with additional follow-up within 16 weeks of initial discharge at a large academic medical system which serves as the primary STEMI PCI center in the Central Texas region. Th e study timeline was selected based on availability of electronic medical records for review. Study data were abstracted from the electronic medical record system, which contained both inpatient and outpatient visits. Th e study received approval from the institutional review board.
Patients were identifi ed as having anterior wall MI based on documentation obtained using the ICD-9 codes for initial episode of care for acute anterior MI (410.0, 410.1). Th ese codes were verifi ed on the hospital discharge summary during manual electronic chart review. Subjects had to meet the following inclusion criteria: received primary PCI (including rescue PCI for failed lytic therapy); received aspirin and an additional P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor); had a predischarge echocardiogram showing extensive wall motion abnormalities (akinetic or hypokinetic segments); and had an EF ≤35%. Patients were excluded if they did not survive to hospital discharge, required anticoagulation for other indications (atrial fi brillation or valvular disease), had no additional follow-up within 16 weeks of initial discharge in the system, or had identifi ed thrombus on predischarge echocardiogram. A 16-week follow-up was utilized since current guidelines recommend 3 months of therapy if actively prophylaxing against LVT formation. Patients were treated according to the discretion of the admitting cardiologists at the time of admission.
Patients were classifi ed into two groups based on the receipt of oral anticoagulation with warfarin. Patients receiving warfarin therapy in addition to aspirin and an additional P2Y12 agent (clopidogrel, prasugrel, or ticagrelor) at discharge were classifi ed as the TT cohort, whereas patients receiving dual therapy with aspirin and an additional P2Y12 agent (clopidogrel, prasugrel, or ticagrelor) were identifi ed as the DAPT cohort.
Th e primary study outcome was the fi rst occurrence of the composite of LVT, cerebrovascular accident, or systemic embolism. Th e primary safety endpoint was major bleeding. Other outcomes included the rate of occurrence of the individual components of the primary outcome and total reported bleeding. LVT was defi ned as a report of possible, probable, or defi nite thrombus on an echocardiogram. Th romboembolic complications were identifi ed as clinical manifestation of acute cerebral or peripheral ischemia diagnosed with objective testing or the clinical diagnosis of transient ischemic attack by a neurologist. Major bleeding was defi ned as fatal bleeding, a decrease in the blood hemoglobin level >4 g/dL, the need for transfusion of >2 units of blood, the need for corrective surgery intervention, and intracranial or intraocular bleeding. Outcomes were identifi ed using ICD-9 codes and were verifi ed by chart review. Th e following ICD-9 codes were used to identify patients and endpoints with verifi cation by chart review: anterior wall MI (410.0-1), ischemic stroke (434), transient ischemic attack (435), blood transfusion (99.0), arterial embolism and thrombosis (444.xx), intracranial hemorrhage (430, 431, 432.x), gastrointestinal bleeding (578), and adverse eff ect related to therapeutic use of anticoagulants (E934.2). Early discontinuation of warfarin was defi ned as discontinuation before 90 days of therapy postdischarge.
Data were analyzed using SPSS Version 21 (IBM Corporation). Continuous variables are reported as means and standard deviation for normally distributed data and as medians for non-normally distributed data. Dichotomous variables are reported as percentages. Comparisons are considered to be signifi cant if the P value is less than an a priori alpha level of 0.05. Comparisons of continuous variables were made with the use of the Student t test for normally distributed data and the Mann-Whitney U test for non-normally distributed data as appropriate. Dichotomous or categorical data were tested by the use of chi-square or Fisher's exact tests where appropriate.
RESULTS
A total of 124 patients met the inclusion criteria, with 80 patients in the DAPT group and 44 patients in the TT group. Th e median hospital length of stay was 4 days, with a median follow-up of 65 days. Th e median peak troponin level was 83 ng/mL. Baseline demographics were similar between both groups, except for age. Patients in the DAPT group were Baylor University Medical Center Proceedings Volume 28, Number 4
signifi cantly older than patients in the TT group (median age of 64 vs. 58 years, P = 0.04). Most patients were male in both groups (60% in DAPT vs. 70.5% in TT, P = 0.25). Other baseline variables are shown in Table 1 . Overall, the insertion of a drug-eluting stent was the most utilized intervention: 71% of patients in the DAPT group received at least one drug-eluting stent, compared with 64% in the TT group (P = 0.38). Clopidogrel was the predominant P2Y12 inhibitor utilized, and patients in the TT group were more likely to be on clopidogrel than patients in the DAPT group (83% vs 96%, P = 0.04). Medications including beta-blockers, statins, and angiotensin-converting enzyme inhibitors were widely used in both groups, as shown in Table 2 .
Th e median estimated EF at baseline was 31% in the DAPT group compared with 30% in the TT group (P = 0.36), and anterior akinesis was described in 79% of patients (80% in the DAPT group vs 77% in the TT group, P = 0.72). A follow-up echocardiogram was performed at a median of 49 days in 82% of patients (81.3% of DAPT group vs 97.7% in TT group). Th e median estimated EF at follow-up was 40% in both groups (P = 0.81). Th ere was a substantial recovery in wall motion abnormality in both groups at follow-up, with 43% described as having apical akinesis compared with 79% at baseline (P < 0.001). Additional information is presented in Table 3 .
Th e mean international normalized ratio at discharge was 1.4 (n = 40), with a third of patients (n = 13) receiving anticoagulant bridge therapy with either low-molecular-weight heparin (n = 10) or unfractionated heparin (n = 3). At follow-up, the mean international normalized ratio was 2.4 (n = 34), with an average length of therapy with warfarin in the TT group of 75 days.
LVT, stroke, or arterial thrombosis occurred in 4 patients receiving DAPT and in 3 patients receiving TT (5.0% vs 6.8%, respectively, P = 0.70; Table 4 ). Patients in the DAPT group had an equal number of incidents of LVT and stroke (2 patients each), whereas there were no reported strokes in patients in the TT group, with LVT being identifi ed in 3 patients. Major bleeding occurred in 1 patient in the DAPT group and none in the TT group, whereas total reported bleeding occurred in 2 patients in the DAPT group and 4 patients in the TT group (2.5% vs 9.1%, respectively, P = 0.18).
DISCUSSION
When we reviewed the outcomes of patients with anterior STEMI complicated by wall motion abnormalities and depressed EF treated with PCI, we found no signifi cant diff erence between those who received TT including warfarin and those receiving DAPT alone.
Th ere are very few studies that have evaluated the benefi ts of TT in patients presumed to be at highest risk of developing LVT. In a natural history study of 198 patients admitted for acute MI in the 1980s, LVT developed only in patients with anterior wall MI (1). Stepwise logistic regression analysis identifi ed anterior location of the infarct, decreased left ventricular EF (<35%), and apical dyskinesia or aneurysm as having the highest association with LVT formation during hospitalization (1) . Consistent with this, we included only patients with EF ≤35% in our study, which resulted in patients in the study having had an estimated median EF of 31%, with anterior akinesis described in 79% of patients.
Given these historic data, we were surprised and pleased that the rate of LVT formation or systemic embolization in our patient cohort was much lower than that reported in the preprimary PCI and thrombolytic era. Clinical embolism occurred in only 1.6% of patients in our study, although no incidents were identifi ed in patients in the TT group. Th e low overall rates of clinical embolism and LVT found are consistent with other studies that have evaluated the clinical course after an acute anterior wall MI in the PCI era (3, 5, 11, 13, 15) . Interestingly, our results also mirror similar results seen in chronic heart failure patients with signifi cant systolic dysfunction (16, 17) . For example, in the WARCEF study of patients with heart failure in sinus rhythm, approximately 40% of whom had an ischemic cardiomyopathy and were randomized to either anticoagulation with warfarin or single antiplatelet therapy with aspirin, no diff erence was found in the rates of death, stroke, or intracerebral hemorrhage between the groups (16). Although there was a benefi t in regards to ischemic stroke in the warfarin study arm, the absolute risk for stroke in the study, similar to our study, was small and was off set by higher bleeding rates.
Navigating the balance between prevention of thromboembolic events and bleeding is paramount when the use of antithrombotic therapy is being considered. As expected, patients in the TT group of our study had higher rates of reported bleeding, although the diff erence was not statistically signifi cant and no major bleed was recorded in the TT group. Th is result must be interpreted cautiously, as we did not have a suffi ciently large enough sample size and patients in the TT group were also signifi cantly younger. A potential reason for the age disparity might be a selection bias by treating physicians, with a preference for triple therapy in younger patients due to a lower perceived bleeding risk. Age is a known risk factor for the development of major bleeds and overall bleeding (18) . Clopidogrel was the most commonly used P2Y12 inhibitor in the TT group; the eff ects of newer and more potent P2Y12 inhibitors such as prasugrel or ticagrelor are unknown and could possibly be associated with a greater bleeding rate.
Th e use of TT has been a subject of recent focus as it relates to patients with atrial fi brillation and need for stenting, but studies of patients perceived at high risk of an LVT remain sparse (19) . Highlighting the paucity of data are recent guideline recommendations from the American Heart Association/ American College of Cardiology Foundation (AHA/ACCF) and the American College of Chest Physicians (ACCP), where the need for TT received low-level recommendations (11, 20) . Th e AHA/ACCF 2013 STEMI guidelines state that anticoagulant therapy "may be considered" for patients with anterior apical akinesis or dyskinesis (Class IIb; Level of Evidence C), while the 9th edition of the ACCP guidelines "suggests" triple therapy (warfarin [INR 2.0-3.0], low-dose aspirin, clopidogrel 75 mg daily) for 1 to 6 months over DAPT (Grade 2C).
Th ere are several limitations to our study. Th is was a retrospective study from a single large tertiary referral center, and we could not account for practice bias. During the study period, the practice guideline recommendations to add warfarin were downgraded from a Class IIa to Class IIb recommendation, and it is possible patients were selected who were thought to most likely benefi t with minimal risk (21) . Th e study had a small sample size, which limited the number of events we were able to evaluate. Th is was especially important given the small absolute number of events found. Another limitation was the lack of serial echocardiogram examinations. It is possible that LVT developed and resolved between periods where the patients had no medical contact with our health system. Additionally, the events captured were based on chart review and ICD-9 codes, which are subject to reporting bias and coding errors.
Despite these limitations, we believe that our data provide important evidence that warfarin may provide signifi cant benefi t to anterior MI patients in an era of prompt PCI and DAPT therapy. Our study highlights the need for larger, prospective studies to better defi ne what role, if any, warfarin and the newer novel oral anticoagulants should play in the management of patients with anterior STEMI and reduced EF (<35%).
